Annual report [Section 13 and 15(d), not S-K Item 405]

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.25.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
CONSOLIDATED STATEMENTS OF OPERATIONS    
Revenues, net $ 7,665 $ 89,160
Operating expenses:    
Cost of implants and other costs 1,667 35,986
Research and development 1,482,877 891,063
Selling, general and administrative 3,612,481 2,875,119
Impairment of intellectual property 0 47,980
Depreciation and amortization 33,145 26,808
Total operating expenses 5,130,170 3,876,956
Loss from operations (5,122,505) (3,787,796)
Other income (expenses):    
Interest expense - related parties (750,773) (692,586)
Interest expense, net (776,780) (194,041)
Loss on settlement of debt (164,602) (34,338)
Grant income 1,473,276 932,996
Other miscellaneous income 129,282 5,275
Total other (expenses) income, net (89,597) 17,306
Loss before provision for income taxes (5,212,102) (3,770,490)
Income taxes 0 0
Net loss (5,212,102) (3,770,490)
Non-controlling interest 105,978 3,577
Net loss attributable to BioCorRx Inc. $ (5,106,124) $ (3,766,913)
Net loss per common share, basic and diluted $ (0.49) $ (0.45)
Weighted average number of common shares outstanding, basic and diluted 10,464,373 8,344,079